Ginkgo Bioworks Inc. (DNA)
NYSE: DNA
· Real-Time Price · USD
10.28
0.27 (2.70%)
At close: Sep 15, 2025, 3:59 PM
10.15
-1.26%
After-hours: Sep 15, 2025, 07:43 PM EDT
2.70% (1D)
| Bid | 10.1 |
| Market Cap | 608.57M |
| Revenue (ttm) | 230.81M |
| Net Income (ttm) | -315.19M |
| EPS (ttm) | -5.76 |
| PE Ratio (ttm) | -1.78 |
| Forward PE | -2.3 |
| Analyst | Hold |
| Ask | 10.32 |
| Volume | 1,192,350 |
| Avg. Volume (20D) | 1,738,909.4 |
| Open | 10.13 |
| Previous Close | 10.01 |
| Day's Range | 9.97 - 10.44 |
| 52-Week Range | 5.00 - 16.85 |
| Beta | 1.51 |
Analyst Forecast
According to 0 analyst ratings, the average rating for DNA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Ginkgo Bioworks Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+14.73%
Ginkgo Bioworks shares are trading higher after th...
Unlock content with
Pro Subscription
5 months ago
+11.23%
Shares of healthcare technology stocks are trading higher. Some stocks in the sector rose after the FDA stated plans to phase out animal testing requirements for monoclonal antibodies and other drugs.
1 month ago · seekingalpha.com
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call TranscriptGinkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason K...
